title: Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
authors.affiliation: Belgian Health Care Knowledge Centre, Boulevard du Botanique, 50, 1000, Brussels, Belgium, maria.farfan@kce.fgov.be.
authors.forename: María-Isabel
authors.initials: MI
authors.lastname: Farfan-Portet
authors.forename: Sophie
authors.initials: S
authors.lastname: Gerkens
authors.forename: Isabelle
authors.initials: I
authors.lastname: Lepage-Nefkens
authors.forename: Irmgard
authors.initials: I
authors.lastname: Vinck
authors.forename: Frank
authors.initials: F
authors.lastname: Hulstaert
mesh_terms: D059451:Biosimilar Pharmaceuticals / Q000191:economics*; D003363:Cost Control; D004465:Economic Competition / Q000191:economics*; D005060:Europe; D005252:Fees, Pharmaceutical; D006801:Humans
chemical_list: D059451:Biosimilar Pharmaceuticals